DE602005021078D1 - Interferon-beta zur antiviralen therapie für atemwegserkrankungen - Google Patents

Interferon-beta zur antiviralen therapie für atemwegserkrankungen

Info

Publication number
DE602005021078D1
DE602005021078D1 DE602005021078T DE602005021078T DE602005021078D1 DE 602005021078 D1 DE602005021078 D1 DE 602005021078D1 DE 602005021078 T DE602005021078 T DE 602005021078T DE 602005021078 T DE602005021078 T DE 602005021078T DE 602005021078 D1 DE602005021078 D1 DE 602005021078D1
Authority
DE
Germany
Prior art keywords
interferon beta
agent
respiratory diseases
antiviral therapy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021078T
Other languages
German (de)
English (en)
Inventor
Donna Elizabeth Davies
Peter Alexander Wark
Stephen Holgate
Sebastian L Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Publication of DE602005021078D1 publication Critical patent/DE602005021078D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE602005021078T 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen Active DE602005021078D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
DE602005021078D1 true DE602005021078D1 (de) 2010-06-17

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021078T Active DE602005021078D1 (de) 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP1734987B1 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2787978A1 (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
JP5172679B2 (ja) * 2005-09-09 2013-03-27 インペリアル イノベーションズ リミテッド 呼吸器疾患の治療のためのインターフェロン−λ療法
AU2005336519B2 (en) * 2005-09-20 2012-05-10 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) * 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
CA2744947A1 (en) * 2008-12-19 2010-10-28 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
CA2782512A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
PL2544705T3 (pl) * 2010-03-12 2017-02-28 Synairgen Research Limited Interferon beta do zastosowania w leczeniu schorzenia dolnych dróg oddechowych powodowanego przez grypę
ES2980738T3 (es) 2010-09-22 2024-10-02 Ena Respiratory Pty Ltd Composición para uso en un método inmunoestimulador
US10246501B2 (en) 2014-01-08 2019-04-02 Prosit Sole Biotechnology (Beijing) Co, Ltd Fusion polypeptides and methods of use
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
US12195557B2 (en) 2017-12-21 2025-01-14 Axelia Oncology Pty Ltd Optimised compounds
US20220233643A1 (en) * 2019-02-13 2022-07-28 University Of Florida Research Foundation, Incorporated TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
BR112021025630A8 (pt) 2019-06-26 2023-04-11 Axelia Oncology Pty Ltd Moléculas novas
US20230338475A1 (en) 2020-07-20 2023-10-26 Synairgen Research Limited USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
EP4240396B1 (en) * 2020-11-04 2025-01-01 Ethris GmbH Ifn-lambda mrna for treating viral infections
KR20220102595A (ko) * 2021-01-13 2022-07-20 에이비온 주식회사 잠재적인 호흡기 바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기 바이러스에 대한 예방적 투여 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
ATE299892T1 (de) * 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US6030609A (en) * 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
AU2002212107A1 (en) 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004037995A2 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US20050244423A1 (en) 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants

Also Published As

Publication number Publication date
EP1734987A2 (en) 2006-12-27
US9089535B2 (en) 2015-07-28
CA2558212C (en) 2012-11-27
US20070134763A1 (en) 2007-06-14
HK1097181A1 (en) 2007-06-22
EP1734987B1 (en) 2010-05-05
EP2206512A3 (en) 2013-01-09
US8273342B2 (en) 2012-09-25
JP2007528890A (ja) 2007-10-18
US7569216B2 (en) 2009-08-04
CA2558212A1 (en) 2005-09-22
PT1734987E (pt) 2010-07-06
GB0405634D0 (en) 2004-04-21
US20090257980A1 (en) 2009-10-15
DK1734987T3 (da) 2010-08-30
ES2343732T3 (es) 2010-08-09
EP2206512A2 (en) 2010-07-14
PL1734987T3 (pl) 2010-10-29
WO2005087253A2 (en) 2005-09-22
WO2005087253A3 (en) 2005-11-24
JP2011144201A (ja) 2011-07-28
US20130209399A1 (en) 2013-08-15
ATE466591T1 (de) 2010-05-15
CA2787978A1 (en) 2005-09-22
JP4807526B2 (ja) 2011-11-02

Similar Documents

Publication Publication Date Title
ATE466591T1 (de) Interferon-beta zur antiviralen therapie für atemwegserkrankungen
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
SG171607A1 (en) Respiratory devices and methods of use
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
JP2011144201A5 (enExample)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
NO20073909L (no) Forstover-formulering
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
BR0307235A (pt) Composição para inalação
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
Schaefer et al. SPLUNC1 Enhances TLR3 Signaling in Mouse Lungs
Mccoy Oxygen Plus.
Miller Combined inhaled bronchodilators in COPD
RU2004130224A (ru) Способ лечения ингаляционной термотоксической травмы

Legal Events

Date Code Title Description
8364 No opposition during term of opposition